Pembro+Chemo as First-Line Standard of Care for Esophageal Cancer

An additional 12 months of follow-up confirmed the benefits of the combination therapy as a first-line treatment for advanced or metastatic esophageal cancer.

Related Keywords

Milan ,Lombardia ,Italy ,United States ,France ,American ,Pembrolizumab Keytruda ,Stefano Cascinu ,Jean Philippe Metges ,American Society Of Clinical Oncology ,European Medicines Agency ,Institut De Cancerologie ,Clinical Oncology ,Gastrointestinal Cancers ,Esophageal Cancer ,San Raffaele Hospital ,Noncolorectal Gastrointestinal Cancer ,Oncolorectal Gi Cancer ,Chemotherapy ,Malignant Esophageal Neoplasm ,Ancer Esophageal ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Neoplasm ,Tumor ,Gastric Cancer ,Alignant Stomach Neoplasm ,Hematology ,Adenocarcinoma ,Adenocarcinoma Gastroesophageal Junction ,Quality Of Life ,Pol ,Ealth Related Quality Of Life , ,